Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-13 4:01 pm Sale | 13G | OCULIS HLDG AG NAMEN AKT OCS | Novartis Bioventures Ltd | 1,713,521 4.7% | -464,381 (-21.32%) | View |
| 2024-02-12 9:06 pm Sale | 13G | OCULIS HLDG AG NAMEN AKT OCS | Pivotal bioVenture Partners Fund I L.P. | 2,414,972 7.4% | -617,324 (-20.36%) | View |
| 2024-02-09 06:47 am Purchase | 13G | OCULIS HLDG AG NAMEN AKT OCS | LSP 7 Cooperative UA | 5,327,362 14.6% | 5,327,362 (New Position) | View |
| 2023-05-04 4:05 pm Purchase | 13G | OCULIS HLDG AG NAMEN AKT OCS | Brunnur vaxtarsjodur slhf | 2,335,841 7.1% | 2,335,841 (New Position) | View |
| 2023-05-02 06:06 am Purchase | 13G | OCULIS HLDG AG NAMEN AKT OCS | BVCF IV L.P. | 2,070,020 6.23% | 2,070,020 (New Position) | View |
| 2023-03-15 12:53 pm Purchase | 13G | OCULIS HLDG AG NAMEN AKT OCS | Pivotal bioVenture Partners Fund I L.P. | 3,032,296 9.3% | 3,032,296 (New Position) | View |
| 2023-03-13 08:01 am Purchase | 13G | OCULIS HLDG AG NAMEN AKT OCS | Novartis Bioventures Ltd | 2,177,902 6.7% | 2,177,902 (New Position) | View |